Flonics
Seoul, KR · 3 known investors
Find your way into Flonics
Flonics develops medical imaging software that automates blood flow analysis using MRI technology for diagnosis and management of cardiovascular and cerebrovascular diseases. The platform provides automated image acquisition, analysis, and reporting alongside a virtual catheter tool to replace invasive procedures.
Also known as FlONICS · Flonics Co., Ltd. · 주식회사 플로우닉스
Investors · 3
Also in the syndicate · 2
Company profile
researched Aug 2026Flonics Co., Ltd. (주식회사 플로우닉스) is a Korean medical imaging software company that develops automated blood flow analysis software and hemodynamic analysis methods for the diagnosis, treatment and management of cardiovascular and cerebrovascular disease. Its products are built on 4D flow MRI, a magnetic resonance imaging technique that captures blood flow motion and patterns in three dimensions over time. The company positions this against conventional shape-based diagnosis, which characterizes vessels by diameter, size and length without blood flow information and therefore cannot readily account for hemodynamics or predict disease onset and progression in conditions such as atherosclerosis, thoracic aortic aneurysm and aortic dissection.
The product line comprises a 4D flow solution that automates image acquisition, analysis and reporting in an all-in-one workflow, and MR-Cath / Virtual-Cath, which derives pressure information from 4D flow MRI as a substitute for invasive catheter-based pressure measurement. The software marketed as "Flonics-Streamliner" visualizes and analyzes flow patterns, velocity and direction within the heart and vessels to support diagnosis, treatment planning and prognosis assessment, and is reported to complete a blood flow analysis in about 30 minutes. Published case reports describe use in aortic dissection patients, including identification of structural bending of blood flow after ascending aorta replacement indicating the need for reoperation, and assessment of renal ischemia to determine whether intervention was required.
The company is headquartered at Kangwon National University in Chuncheon, Gangwon-do, and its stated industry is medical imaging software development.
Founding story
Flonics was incorporated on May 10, 2024 as a spin-out grounded in roughly a decade of Korean national research projects on 4D flow MRI. CEO Hojin Ha, a professor at Kangwon National University (mechanical / biomedical and mechatronics engineering) with a PhD from POSTECH and postdoctoral work at Asan Medical Center and Linköping University in Sweden, led several of these projects. He co-founded the company with Donghyun Yang, a radiology professor at Asan Medical Center and head of its cardiac imaging center, and Junegu Lee, a research associate professor at the Asan Institute for Life Sciences specializing in medical image processing and AI.
Business model
Flonics develops and licenses medical imaging analysis software to hospitals and research institutions. Following its seed round the company stated it intends to introduce a usage-based pricing model positioned as a cost-efficient alternative for hospitals and research institutions.
Software for hospitals and research institutions; the company has stated it intends to adopt usage-based pricing.
Traction
Flonics has completed or is running multiple National Research Foundation of Korea projects underpinning its technology, was selected for several Korean government startup and technology-commercialization programs in 2024 and 2025 including the Ministry of Science and ICT Deep Science Startup Activation Program, publishes clinical case reports from aortic dissection patients, and raised seed capital in August 2025. As of that announcement the product was pre-prototype-completion, with prototype completion targeted within 2025 and regulatory approval targeted the following year.
Latest developments
In August 2025 Flonics announced seed funding led by Kakao Ventures with participation from Digital Healthcare Partners and Kangwon National University Holdings. The company said it would complete prototype development of Flonics-Streamliner within the year, advance technical sophistication, validate clinical efficacy, expand collaborations with domestic and international institutions including Asan Medical Center, and target domestic regulatory approval and global market entry the following year.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
An early-stage Korean medical imaging software company focused on the clinical application of 4D flow MRI for cardiovascular and cerebrovascular hemodynamics, backed by venture investors and multiple national R&D and startup support programs, and operating at prototype stage prior to regulatory approval.
Flonics contrasts its approach with conventional imaging that interprets static vascular morphology only, arguing that time-resolved 4D flow MRI reveals subtle pathological changes and hemodynamic biomarkers that shape-based measurements of diameter, size and length cannot provide. It also offers a virtual catheter capability intended to replace invasive catheter pressure measurement, and an automated end-to-end acquisition-analysis-reporting workflow developed in collaboration with clinicians.
Technology
The core technology is 4D flow MRI, which measures three-dimensional, time-resolved blood flow motion and patterns. Flonics builds automated image acquisition, post-processing, analysis and reporting on top of it, deriving hemodynamic biomarkers for integrated vascular-and-flow diagnosis, disease prediction and post-procedural flow monitoring. MR-Cath / Virtual-Cath computes pressure information non-invasively as an alternative to catheter measurement. Stated internal capabilities include MRI image analysis and reconstruction, computational simulation, in-vitro validation using patient-specific 3D-printed blood flow phantoms, and AI-based denoising and super-resolution.
Go-to-market
The company works closely with clinicians and academic medical centers, notably Asan Medical Center, to validate clinical efficacy and refine usability, and publishes clinical case reports. It plans to obtain domestic regulatory approval before expanding internationally, selling to hospitals and research institutions on a usage-based pricing basis.
Hospitals, cardiac imaging and radiology departments, clinicians treating cardiovascular and cerebrovascular disease (including atherosclerosis, thoracic aortic aneurysm and aortic dissection), and research institutions.
Geography
Headquartered in Chuncheon, Gangwon-do, Republic of Korea, at Kangwon National University (Bodum Room 905, 1 Kangwondaehak-gil). The company plans to pursue domestic Korean regulatory approvals and subsequently enter global markets, and to expand collaborations with domestic and international institutions such as Asan Medical Center.
History
The company's technical foundation comes from a series of National Research Foundation of Korea projects on 4D flow MRI running from 2015 onward, led by principal investigators including Hojin Ha, Donghyun Yang, Namguk Kim and Eunbo Shim, covering in-vivo flow characterization of cardiovascular disease, non-invasive hemodynamic diagnosis, turbulence measurement, and an integrated platform for 3D blood flow measurement and computational analysis (2021-2026). Flonics Co., Ltd. was established on May 10, 2024. During 2024 it was selected for the University-based Preliminary Startup Package, the G-Startup Preliminary Startup Package, the University IP Commercialization Support Program (BRIDGE 3.0) and a university startup scale-up program, followed in 2025 by the University-based Initial Startup Package and the Deep Science Startup Activation Support Program (Type 2). In August 2025 the company announced seed funding from Kakao Ventures, Digital Healthcare Partners and Kangwon National University Holdings.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 4
launches, deals, and filingsFlonics announced seed funding from Kakao Ventures, Digital Healthcare Partners (DHP) and Kangwon National University Holdings, with Kakao Ventures leading. Proceeds are earmarked for completing prototype development of Flonics-Streamliner, clinical validation, and pursuit of domestic regulatory approval ahead of global expansion.
Flonics participated in the Ministry of Science and ICT's Deep Science Startup Activation Program; the company history also lists a 2025 University-based Initial Startup Package.
Company incorporation date listed on the corporate profile page, with Hojin Ha as CEO.
Company history lists 2024 participation in the University-based Preliminary Startup Package, G-Startup Preliminary Startup Package, University IP Commercialization Support Program (BRIDGE 3.0), and the University-based Startup Open Tech Call Center Scale-up Program, with CEO Hojin Ha.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Flonicsflonics.co.kr · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Flonics do?
- Korean medical imaging software company building 4D flow MRI-based automated blood flow analysis for cardiovascular and cerebrovascular disease.
- Who are Flonics's investors?
- Flonics's investors include Kakao Ventures.
- Where is Flonics headquartered?
- Flonics is headquartered in Seoul, KR.